Dr. Lang is the President of Axis Therapeutics Limited. He also serves as a Senior Director of Corporate Development at Athenex, Inc. Dr. Lang brings to Axis over 25 years of medicine, healthcare investment as well leadership and business experience. Prior to joining Axis, Dr. Lang was the Chief Investment Officer of the RS Value franchise focused on domestic equity strategies. He was on the executive team of RS Investment Management (RSIM) that led the sale of RSIM to Victory Capital in 2016. Prior to joining RSIM in 2009, he was an analyst at Farallon Capital Management covering biotech, medical device, pharma, and healthcare services globally. Previously, he was a senior associate at a venture capital firm, Brilleon Capital and the co-founder and CFO of Sapient Medical Group. Dr. Lang’s 25+ years of business and investment experience is preceded by a distinguished career in medicine. He was a post-doctoral research and clinical fellow in cardiology at the University of California, San Francisco and the Gladstone Cardiovascular Research Institute. He was board certified in internal medicine and a Chief Medical Resident at Mount Sinai Hospital in New York. Dan holds a BA in Chemistry from Cornell University and an MD from Cornell University Medical College.